

Please type a plus sign (+) inside this box



JAN 07 1999

PTO/SB/08A (10-96

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
Application Number	09/020,393				
Filing Date	February 9, 1998				
First Named Inventor	Dr. Peter J. Sims				
Group Art Unit	Not yet assigned 1644				
Examiner Name	Not yet assigned				
Attorney Docket Number	OMRF 170				

U.S. PATENT DOCUMENTS						
Examiner's Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
M		3,625,214		Higuchi	05-18-1970	
		4,244,946		Rivier, et al.	01-13-1981	
		4,305,872		Johnston, et al.	12-15-1981	
		4,316,891		Guillemin, et al.	02-23-1982	
		4,447,415		Rock	05/08/84	
		4,629,784		Stammer	12-16-1986	
		4,695,460		Holme	09/22/87	
		4,789,734		Pierschbacher	12-06-1988	
		4,792,525		Ruoslahti, et al.	12-20-1988	
		4,906,474		Langer, et al.	03-06-1990	
		4,916,219		Linhardt, et al.	04-10-90	
		4,925,673		Steiner, et al.	05-15-1990	
		5,136,916		Shibukawa	08-11-1992	
		5,612,895		Balaji, et al.	03-18-1997	
		5,573,940		Sims, et al.	11/12/96	
M		5,624,837		Fodor, et al.	04/29/97	
		5135916		SIMS ET AL.	08/04/97	

FOREIGN PATENT DOCUMENTS								
Examiner's Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
m			0,351,313	EPA		07/11/89		
			0,394,035	EPA		04/14/90		
m			WO 93/01286	PCT		01/21/93		
			WO 97/17987	PCT		05/22/97		

Examiner's Signature	Philip Gamber	Date Considered	6/7/99
----------------------	---------------	-----------------	--------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

X +



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/020,393
		Filing Date	February 9, 1998
		First Named Inventor	Dr. Peter J. Sims
		Group Art Unit	Not yet assigned (1644)
		Examiner Name	Not yet assigned
Sheet 2 of 14	Attorney Docket Number	OMRF 170	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
u		AGRAWAL, et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus," <i>Proc. Natl. Acad. Sci. USA</i> 85(19):7079-7083 (1988).	
		ALLEN, et al., "The Cambridge Crystallographic Data Centre: Computer-Based Search, Retrieval, Analysis and Display of Information," <i>Acta Cryst. B</i> 35:2331-2339 (1979).	
		AMIES, "The Use of Topically Formed Calcium Alginate as a Depot Substance in Active Immunisation" <i>J. Path. Bact.</i> 77:435-442 (1959).	
		ANDO, et al., "The Secretory Release Reaction Initiated by Complement Proteins C5b-9 Occurs Without Platelet Aggregation Through Glycoprotein II-b-IIIa," <i>Blood</i> 73(2):462-467 (1989).	
		ANDO, et al., "Complement Proteins C5b-9 Initiate Secretion of Platelet Storage Granules without Increased Binding of Fibrinogen or von Willebrand Factor to Newly Expressed Cell Surface GPIIb-IIIa," <i>J. Biol. Chem.</i> 263(24):11907-11914 (1988).	
		ARCHAKOV, et al., <i>Vestn. Ross. Akad. Med. Nauk.</i> 1:60-63 (1996).	
		ASKEW, et al., "Molecular recognition with Convergent Functional Groups" <i>J. Am. Chem. Soc.</i> , 111:1082-1090 (1989)	
		BEVERS, et al., al. "Defective Ca ²⁺ - Induced microvesiculation and deficient Expression of Procoagulant Activity in Erythrocytes From a patient with a Bleeding Disorder" A Study of the Red Blood Cells of Scott Syndrome" <i>Blood</i> 79(2): 380-388 (1992).	
		BLAAS, et al., "Paroxysmal Nocturnal Hemoglobinuria" <i>J. Immunology</i> 140:3045-3051 (1988).	
		BODIAN, et al., al., "Mutational Analysis of the Active Site and Antibody Epitopes of the Complement-inhibitory Glycoprotein CD59," <i>J. Exp. Med.</i> 185(3):507-516 (1997).	
u		BRAGA, et al. "A Monoclonal Antibody to the Galactose-Specific Adhesin Abrogates the resistance of <i>E. histolytica</i> to Lysis by Human Complement C5b-9" <i>XIV International Complement Workshop</i> Cambridge, U.K. (1991).	
Examiner's Signature	Phim GAMBEL 6/7/99		Date Considered


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

X +



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/020,393
		Filing Date	February 9, 1998
		First Named Inventor	Dr. Peter J. Sims
		Group Art Unit	Not yet assigned (1644)
		Examiner Name	Not yet assigned
Sheet 3 of 14	Attorney Docket Number	OMRF 170	

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
me		BRINT, "Upperbound procedures for the identification of similar three-dimensional chemical structures," et al., <i>J. Comput.-Aided Mol. Design</i> 2:311-310 (1988).	
		BURGESS, et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-bind Activities by Site-directed Mutagenesis of a Single Lysine Residue," <i>J. Cell Biology</i> 111:2129-2138 (1990).	
		CHANG, et al. "Identity of a Peptide Domain of Human C9 That Is Bound by the Cell-surface Complement Inhibitor, CD59," <i>J. Biol. Chem.</i> 269(42):26424-26430 (1994).	
		CLACKSON, et al., "Making antibody fragments using phage display libraries," <i>Nature</i> 352:624-688 (1991).	
		COOPER, et al., "A novel approach to molecular similarity," <i>J. Comput.-Aided Mol. Design</i> 3:253-259 (1989).	
		CROSS, "Glycolipid Anchoring of Plasma Membrane Proteins" <i>Annu. Rev. Cell Biol.</i> 6:1-39 (1990).	
		DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," <i>Nucl. Acids Res.</i> 19(9):2471-2476 (1991).	
		DAVIES, et al., "CD59, An LY-6-Like Protein Expressed in Human Lymphoid Cells, Regulates the Action of the Complement Membrane Attack Complex on Homologous Cells," <i>J. Exp. Med.</i> 170(3):637-654 (1989).	
		DAVIES, et al. "Membrane Defense against Complement Lysis: The Structure and Biological Properties of CD59," <i>Immunol. Res.</i> 12(3):258-275 (1993).	
		DUPUIS, et al., "Mutations in the Putative Lipid-Interaction Domain of Complement C9 Result in Defective Secretion of the Functional Protein," <i>Mol. Immunol.</i> 30(1):95-100 (1993).	
me		FLETCHER, et al., "Sequence-specific ¹ H-NMR assignments and folding topology of human CD59," <i>Protein Sci.</i> 2:2015-2027 (1993).	
Examiner's Signature	PHILIP GAMBEL 6/7/99		Date Considered


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

X +



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/020,393
				Filing Date	February 9, 1998
				First Named Inventor	Dr. Peter J. Sims
				Group Art Unit	Not yet assigned 1644
				Examiner Name	Not yet assigned
Sheet	4	of	14	Attorney Docket Number	OMRF 170

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
W		FLETCHER, et al., "Structure of soluble, glycosylated form of the human complement regulatory protein CD59," <i>Structure</i> 2:185-199 (1994).	
		GERBER, et al., "Phosphatidylinositol Glycan (PI-G) Anchored Membrane Proteins," <i>J. Biol. Chem.</i> 267(17):12168-12173 (1992).	
		GHOSHAL, et al., "Computer Aids in Drug Design - Highlights" <i>Pol. J. Pharmacol.</i> 48(4): 359-377 (1996).	
		GILBERT, et al. "Platelet-derived Microparticles Express High Affinity Receptors for Factor VIII" <i>J. Biol. Chem.</i> 266(8): 1-8 (1991).	
		GREGORIADIS, "Liposomes," in <i>Drug Carriers in Biology and Medicine</i> , Chap. 14. pp. 287-341 (Academic Press, 1979).	
		GROUX, et al., "A 19-kDa Human Erythrocyte Molecule H19 is Involved in Rosettes, Present on Nucleated Cells, and Required for T Cell Activation," <i>J. Immunology</i> 142(9):3013-3020 (1989).	
		HAHN, et al. "Overlapping But Nonidentical Binding Sites on CD2 for CD58 and a second Ligand CD59" <i>Science</i> 256: 1805-1807 (1992).	
		HAMILTON, et al. "The Terminal Complement Proteins C5b-9 Augment Binding of High Density Lipoprotein and its Apolipoproteins A-I and A-II to Human Endothelial Cells" <i>J. Clin. Invest</i> 88: 1833-1840 (1991).	
		HAMILTON, et al., "Complement Proteins C5b-9 Induce Vesiculation of the Endothelial Plasma Membrane and Expose Catalytic Surface for Assembly of the Prothrombinase Enzyme Complex" <i>J. Bio. Chem.</i> , 265:3809-3814 (1990)	
		HAMILTON, et al., "Regulatory Control of the Terminal Complement Proteins at the Surface of Human Endothelial Cells: Neutralization of a C5b-9 Inhibitor by Antibody to CD59," <i>Blood</i> 76(12):2572-2577 (1990).	
W		HAMILTON, et al, "Regulatory Control of he Terminal Proteins at the Surface of Human Endothelial Cells: Neutralization of a C5b-9 Inhibitor by Antibody to CD59," <i>Blood</i> 76(12): 2572-2577 (1990).	
Examiner's Signature	PHILIP GAMBEL 6/7/99		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

X +

JAN 07 1999

PTO/SB/08A (10-96 +

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/020,393
				Filing Date	February 9, 1998
				First Named Inventor	Dr. Peter J. Sims
				Group Art Unit	Not yet assigned 1644
				Examiner Name	Not yet assigned
Sheet	5	of	14	Attorney Docket Number	OMRF 170

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
ue		HANSCH, et al. "Paroxysmal Nocturnal Hemoglobinuria Type III" <i>J. Clin. Invest.</i> 80:7-12 (1987).	
		HANSCH, et al., "Release of C8 Binding Protein (C8bp) From the Cell Membrane by Phosphatidylinositol-Specific Phospholipase C," <i>Blood</i> 72(3):1089-1092 (1988).	
		HARADA, et al., "Monoclonal antibody G6K12 specific for membrane-associated differentiation marker of human stratified squamous epithelia and squamous cell carcinoma," <i>J. Oral Pathol. Med.</i> (Denmark), 22(4):145-152 (1993).	
		HATANAKA, et al., "The functions of the ninth component of human complement are sustained by disulfide bonds with different susceptibilities to reduction," <i>Biochim. Biophys. Acta Protein Struct. Mol. Enzymol.</i> 1209(1):117-122 (1994).	
		HATTORI, et al. "Complement Proteins C5b-9 Induce Secretion of High Molecular Weight Multimers of Endothelial von Willebrand Factor and Translocation of Granule Membrane Protein GMP-140 to the Cell Surface," <i>J. Biol. Chem.</i> 264(15):9053-9060 (1989).	
		HATTORI, et al., "Stimulated Secretion of Endothelial von Willebrand Factor Is Accompanied by Rapid Redistribution to the Cell Surface of the Intracellular Granule Membrane Protein GMP-140" <i>J. Bio. Chem.</i> , 264(14):7768-7771 (1989)	
		HOGAN, et al., <i>Manipulating Mouse Embryo: a Laboratory Manual</i> Cold Spring Harbor Laboratory (1986)	
		HOLGUIN, et al., "Isolation and Characterization of a Membrane Protein from Normal Human Erythrocytes That Inhibits Reactive Lysis of the Erythrocytes of Paroxysmal Nocturnal Hemoglobinuria," <i>J. Clin. Invest.</i> 84(1):7-17 (1989).	
		HOULE, et al., "Evidence for restriction of the ability of complement to lyse homologous Erythrocytes," <i>J. Immunol.</i> 133:1444-1452 (1984).	
		HOULE, et al., "Restriction of Cell Lysis by Homologous Complement: II. Protection of Erythrocytes Against Lysis by Newly Activated Complement," <i>Blood</i> 71(2):287-292 (1988).	
		HUANG et al., "Development of a Common 3D Pharmacophore for Delta-Opioid Recognition From Peptides and Non-Peptides Using a Novel Computer Program" <i>J. Comput. Aided Mol. Des.</i> 11(1):21-78 (1997).	
		HUSLER, et al., "Chimeras of Human Complement C9 Reveal the Site Recognized by Complement Regulatory Protein CD59," <i>J. Biol. Chem.</i> 270(8):3483-3486 (1995).	
Examiner's Signature	PHILLIP GAMBEL 6/7/99		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

X +

JAN 07 1999



PTO/SB/08A (10-96 +

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/020.393
				Filing Date	February 9, 1998
				First Named Inventor	Dr. Peter J. Sims
				Group Art Unit	Not yet assigned 1674
				Examiner Name	Not yet assigned
Sheet	6	of	14	Attorney Docket Number	OMRF 170


OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
mc		HUSLER, et al., "Role of a Disulfide-bonded Peptide Loop within Human Complement C9 in the species-Selectivity of Complement Inhibitor CD59", <i>Biochem.</i> , 35(10):3263-3269 (1996)	
		INAL, et al., "Immunohistochemical detection of an enamel protein-related epitope in rat bone at an early stage of osteogenesis," <i>Histochemistry</i> (Germany), 99(5):335-362 (1993).	
		ITAKURA, et al., "Synthesis and Use of Synthetic Oligonucleotides," in <i>Ann. Rev. Biochem.</i> 53:323-356 (1984).	
		KABAT, et al., Sequences of Proteins of Immunological Interest, 4th Ed. (U.S. Dept. Health and Human Services, Bethesda, MD, 1987)	
		KIEFFER, et al., "Three-Dimensional Solution Structure of the Extracellular Region of the Complement Regulatory Protein CD59, a New Cell-Surface Protein Domain Related to Snake Venom Neurotoxins," <i>Biochemistry</i> 33:4471-4482 (1994).	
		KINOSHITA, et al., "Defective Glycosyl Phosphatidylinositol Anchor Synthesis and Paroxysmal Nocturnal Hemoglobinuria," <i>Adv. Immunol.</i> 60:57-103 (1995).	
		KLEINBERG, et al., "New Approaches and Technologies in Drug Design and Discovery" <i>Am. J. Health Syst. Pharm.</i> 52(12):1323-1336 (1995).	
		KOORYMAN, et al. "In Vivo Transfer of GPI-Linked Complement Restriction Factors from Erythrocytes to the Endothelium" <i>Science</i> 269:89-92 (1995).	
		KORTY, et al. "'CD59 Functions as a Signal-Transducing Molecule for Human T Cell Activation" <i>J. Immunol.</i> 146:4092-4098 (1991)	
		KUBINYI, "Strategies and Recent Technologies in Drug Discovery" <i>Pharmazie</i> 50(10):647-662 (1995).	
m		LAZAR, et al., "Transforming Growth Factor :Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <i>Molecular and Cellular Biology</i> 8(3):1247-1252 (1988).	
Examiner's Signature	PHILLIP GAMBER 6/7/99		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/020,393
				Filing Date	February 9, 1998
				First Named Inventor	Dr. Peter J. Sims
				Group Art Unit	Not yet assigned 1641
				Examiner Name	Not yet assigned
Sheet	7	of	14	Attorney Docket Number	OMRF 170

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
PG		LEWIS, et al., "Automated site-directed drug design: the concept of spacer skeletons for primary structure generation," <i>Proc. R. Soc. Lond.</i> , 236(1283):125-140 (1989)	
		LEWIS, et al., "Automated site-directed drug design: the formation of molecular templates in primary structure generation," <i>Proc. R. Soc. Lond.</i> , 236(1283):141-162 (1989)	
		LI, et al., "A computer Screening Approach to Immunoglobulin Superfamily Structures and Interactions: Discovery of Small Non-Peptide CD4 Inhibitors and Novel Immunotherapeutics" <i>Proc. Natl. Acad. Sci. USA</i> 94(1):73-78 (1997).	
		LIN, et al. "A family showing inheritance of the Inab phenotype" <i>Transfusion</i> 28: 427-429 (1988).	
		LUBLIN, et al., "Decay-Accelerating Factor and Membrane Cofactor Protein," <i>Current Topics Microbiol. Immunol.</i> 153:123-145 (1989).	
		LYBRAND, "Ligand-Protein Docking and Rational Drug Design" <i>Curr. Opin. Struct. Biol.</i> 5(2):224-228 (1995).	
		MARTIN, et al., "Induction of expression of cell-surface homologous restriction factor upon anti-CD3 stimulation of human peripheral lymphocytes," <i>Proc. Natl. Acad. Sci. USA</i> 85:213-217 (1988).	
		MCKINLAY, et al., "Rational Design of Antiviral Agents," <i>Annual Review of Pharmacology and Toxicology</i> , 29:111-122 (1989)	
		MEDOF, et al., "Inhibition of Complement Activation on the Surface of Cells After Incorporation of Decay-Accelerating Factor (DAF) Into Their Membranes," <i>J. Exp. Med.</i> 160(5):1558-1578 (1984).	
		MERRIFIELD, "Solid-Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide," <i>J. Am. Chem. Soc.</i> 85:2149-2154 (1964).	
M		MULDER, et al., "Characterization of Two Human Monoclonal Antibodies Reactive with HLA-B12 and HLA-B60, Respectively, Raised by <i>in vitro</i> Secondary Immunization of Peripheral Blood Lymphocytes," <i>Hum. Immunol.</i> 36(3):186-192 (1993).	
Examiner's Signature	PHILIP GAMBER 6/7/99		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

X +

JAN 07 1999

PTO/SB/08A (10-96 +
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/020,393
				Filing Date	February 9, 1998
				First Named Inventor	Dr. Peter J. Sims
				Group Art Unit	Not yet assigned 1644
				Examiner Name	Not yet assigned
Sheet	8	of	14	Attorney Docket Number	OMRF 170

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
M		NAKANO, et al., "Determination of the Active Site of CD59 with Synthetic Peptides," <i>Mol. Immunol.</i> 32(4):241-247 (1995).	
		NARANG, et al., "Chemical Synthesis of Deoxyoligonucleotides by the Modified Triester Method," in <i>Methods Enzymol.</i> 65:610-620 (1980).	
		NELSON, et al., at pp. 227, 271 and 285, respectively, in <i>Burger's Medicinal Chemistry</i> , Part 1, the <u>Basis of Medicinal Chemistry</u> , 4th Edition, (Wolff, ed.) (John Wiley & Sons, NY, 1980).	
		# NICHOLSON-WELLER, et al., "Surface Membrane Expression by Human Blood Leukocytes and Platelets of Decay-Accelerating Factors, a Regulatory Protein of the Complement System," <i>Blood</i> 65(5): 1237-1244 (1985).	
		NINOMIYA, et al., "The Human Complement Regulatory Protein CD59 Binds to the α -Chain of C8 and to the "b" Domain of C9," <i>J. Biol. Chem.</i> 267:13675-13680 (1992).	
		NINOMIYA, et al. "Contribution of the N-Linked Carbohydrate of Erythrocyte Antigen CD59 to ITS Complement -inhibitory Activity" <i>J. Biol. Chem.</i> 267(12): 8404-8410 (1992).	
		NOSE, et al. "Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells <i>in vivo</i> " <i>Immunology</i> 70:145-149 (1990).	
		OFFENSBERGER, et al., "In Vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides," <i>EMBO J.</i> 12(3):1257-1262 (1993).	
		OKADA, et al. "Monoclonal Antibodies Capable of Causing Hemolysis of Neuraminidase-treated Human Erythrocytes by Homologous Complement" <i>J. Immunol.</i> 143: 2262-2266 (1989).	
		OKADA, et al., "20 Kda Homologous Restriction Factor of Complement Resembles T Cell Activating Protein," <i>Biochem. Biophys. Res. Comm.</i> 162(3):1553-1559 (1989).	
M		OKADA, et al., "A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement," <i>International Immunology</i> 1(2):205-208 (1989).	
Examiner's Signature	PHILIP GAMBER 6/7/99		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

X +

JAN 07 1999

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/020,393
		Filing Date	February 9, 1998
		First Named Inventor	Dr. Peter J. Sims
		Group Art Unit	Not yet assigned 1644
		Examiner Name	Not yet assigned
Sheet 9 of 14	Attorney Docket Number	OMRF 170	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
M		PANGBURN, et al., "Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria," <i>Proc. Natl. Acad. Sci. USA</i> 80:5430-5434 (1983).	
1		PERRY & DAVIES, <u>QSAR: Quantitative Structure-Activity Relationships in Drug Design</u> pp. 189-193 (Alan R. Liss, inc. 1989)	
		PETRANKA, et al., "Structure-Function Relationship of the Complement Regulatory Protein, CD59," <i>Blood Cells Mol. Dis.</i> 22(3):281-296 (1996).	
		PHILBRICK, et al., "The CD59 antigen is a structural homologue of murine Ly-6 antigens but lacks interferon inducibility," <i>Eur. J. Immunol.</i> 20: 87-92 (1990).	
		PLATT, et al., "Transplantation of discordant xenografts: a review of progress" <i>Immunology Today</i> 11(12): 450-457 (1990).	
		RIPKA, "Computers Picture the Perfect Drug," <i>New Scientist</i> , 54-57 (June 16, 1988)	
		ROLLINS, et al., "The Complement-Inhibitory Activity of CD59 Resides in its Capacity to Block Incorporation of C9 Into Membrane C5b-9," <i>J. Immunol.</i> 144(9):3478-3483 (1990).	
		ROLLINS, et al., "Inhibition of Homologous Complement by CD59 is Mediated by a Species-Selective Recognition Conferred Through Binding to C8 Within C5b-8 or C9 Within C5b-9," <i>J. Immunol.</i> 146(7):2345-2351 (1991).	
		ROTIVINEN, et al., "Computer-Aided Drug Design," <i>Acta Pharmaceutica Fennica</i> , 97:159-166 (1988)	
M		SARIN, et al., "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates," <i>Proc. Natl. Acad. Sci. USA</i> 85(20):7448-7794 (1989).	
Examiner's Signature	Philip G. M. M. 6/7/99		Date Considered


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

X +



PTO/SB/08A (10-96 +
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/020,393
				Filing Date	February 9, 1998
				First Named Inventor	Dr. Peter J. Sims
				Group Art Unit	Not yet assigned 1644
				Examiner Name	Not yet assigned
Sheet	10	of	14	Attorney Docket Number	OMRF 170


OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		SCHALLER, et al., "Identification of the Disulfide Bonds of the Human Complement Component C9 and Comparison with the Other Terminal Components of the Membrane Attack Complex," <i>J. Protein Chem.</i> 13:472-473 (1994).	
		SCHÖNERMARK, et al., "The C8-binding protein of human erythrocytes: interaction with the components of the complement-attack phase," <i>Immunology</i> 63(4):585-590 (1988)	
		SCHÖNERMARK, et al., "Homologous Species Restriction in Lysis of Human Erythrocytes: A Membrane-Derived Protein with C8-Binding Capacity Functions as an Inhibitor," <i>J. Immunol.</i> 136(5):1772-1776 (1986).	
		SHATTIL, et al., "Changes in the Platelet Membrane Glycoprotein IIb-IIIa Complex during Platelet Activation," <i>J. Biol. Chem.</i> 260():11107-11112 (1985).	
		SHAW, et al., "Modified deoxyoligonucleotides stable to exonuclease degradation in serum," <i>Nucleic Acids Res.</i> 19(4):747-750 (1991).	
		SHIN, et al., "Membrane Factors Responsible for Homologous Species Restriction of Complement-Mediated Lysis: Evidence for a Factor Other Than DAF Operating at the Stage of C8 and C9," <i>J. Immunology</i> 136(5):1777-1782 (1986).	
		SHIN, et al., "Cytotoxic Action and Other Metabolic Consequences of Terminal Complement Proteins," <i>Prog. Allergy</i> 40:44-81 (1988).	
		SIMS, "Interaction of Human Platelets with the Complement System", <i>Platelet Immunobiology</i> , Chapter 18, 354-383 (1990)	
		SIMS, "Complement Protein C9 Labeled with Fluorescein Isothiocyanate Can Be Used to Monitor C9 Polymerization and Formation of the Cytolytic Membrane Lesion" <i>Biochemistry</i> 23: 3248-3260 (1984).	
		SIMS, et al. "The response of human platelets to activated components of the complement system" <i>Immunology Today</i> 12(9): 338-342 (1991).	
		SIMS, et al., "Assembly of the Platelet Prothrombinase Complex Is Linked to Vesiculation of the Platelet Plasma Membrane," <i>J. Biol. Chem.</i> 264(29):17049-17057 (1989).	
Examiner's Signature	PHILIP GAMBER 6/7/99		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96 +
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/020,393
				Filing Date	February 9, 1998
				First Named Inventor	Dr. Peter J. Sims
				Group Art Unit	Not yet assigned 1644
				Examiner Name	Not yet assigned
Sheet	11	of	14	Attorney Docket Number	OMRF 170

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
M		SIMS, et al., "Complement Proteins C5b-9 Cause Release of Membrane Vesicles for the Platelet Surface That Are Enriched in the Membrane Receptor for Coagulation Factor VA and Express Prothrombinase Activity," <i>J. Biol. Chem.</i> 263(34):18205-18212 (1988).	
		SIMS, et al., "Regulatory Control of Complement on Blood Platelets," <i>J. Biol. Chem.</i> 264(32):19228-19235 (1989).	
		SIMS, et al., "Repolarization of the Membrane Potential of Blood Platelets After Complement Damage: Evidence for a Ca ²⁺ -Dependant Exocytotic Elimination of C5b-9 Pores," <i>Blood</i> 68(2):556-561 (1986).	
		SIMS, "Plasma Proteins; Complement" in <i>Transfusion Medicine</i> , pp. 1582-1591, (Mintz, ed.) W.B. Saunders, Philadelphia (1994-1995)	
		SLANETZ, et al. "Heterodimeric, disulfide-linked α/β T cell receptors in solution" <i>Eur. J. Immunol.</i> 21: 179-183 (1991).	
		SPATOLA, <i>Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins</i> Vol. 7, pp. 257-357, (Weinstein, B, Ed.), Marcel Dekker, New York (1983).	
		STAUBER, et al., "Rapid generation of monoclonal antibody-secreting hybridomas against African horse sickness virus by <i>in vitro</i> immunization and the fusion/cloning technique," <i>J. Immunol. Methods</i> (Netherlands), 161(2):157-168 (1993).	
		STEFANOVA, et al., "Characterization of a Broadly Expressed Human Leucocyte Surface Antigen MEM-43 Anchored in Membrane Through Phosphatidylinositol," <i>Molecular Immunology</i> 26(2):153-161 (1989).	
		STEWART, et al., "Orientation of Human CD59 Upon Insertion into the Phospholip Bilayer. A Fluorescent Resonance Energy Transfer Study" <i>Biophysical Journal</i> 59:48 (1991). (abstract)	
		SUGITA, et al. "Isolation from Human Erythrocytes of a New Membrane Protein Which Inhibits the Formation of Complement Transmembrane Channels," <i>J. Biochem</i> 104: 633-637 (1988).	
M		SZELKE, et al., <i>In Peptides: Structure and Function, Proceedings of the Eighth American Peptide Symposium</i> , (Hruby, et al., eds.) pp. 579-582, (Pierce Chemical Co., Rockford, Ill. (1983).	
Examiner's Signature	PHILIP GAMBER 6/7/99		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

X +

JAN 07 1999



PTO/SB/08A (10-96

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/020,393
				Filing Date	February 9, 1998
				First Named Inventor	Dr. Peter J. Sims 1644
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	12	of	14	Attorney Docket Number	OMRF 170


OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
M		SZOSTAK, "In Vitro genetics," <i>TIBS</i> 19:89-93 (1992).	
7		TAO, et al., "Studies of Aglycosylated Chimeric Mouse-Human IgC," <i>J. Immunology</i> 43(8):2595-2601 (1989).	
		TAKEBE, et al. "SRα Promoter: an efficient and Veratile mammalian cDNA Expression System Composed of the simian Virus 40 Early Promoter and the R-U5 Segment of Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat" <i>Mol. Cell. Biol</i> 8(1): 466-472 (1988).	
		TAYLOR, et al., "The Word Wide Web as a graphical user interface to program macros for molecular graphics, molecular modeling, and structure-based drug design" <i>J. Mol. Graph.</i> 14(5):291-296 (1996).	
		TELEN, "Identification of Human Erythrocyte Blood Group Antigens on Decay-Accelerating Factor (DAF) and an Erythrocyte Phenotype Negative for DAF" <i>J. Exp. Med</i> 167: 1993-1998 (1988).	
		TERSTAPPEN, et al. "Expression of the DAF (CD55) and CD59 antigens during normal hemotopoietic cell differentiation" <i>Journal of Leukocyte Biology</i> 52:652-660 (1992).	
		VAN DE MEER, et al., "Complement Proteins C5b-9 Induce Transbilayer Migration of Membrane Phospholipids," <i>Biophys. J.</i> 56:935-946 (1989)	
		VENKATESWARAN, et al., "Production of Anti-Fibroblast Growth Factor Receptor Monoclonal Antibodies by In Vitro Immunization," <i>Hybridoma</i> 11(6):729-739 (1992).	
		WEINER, et al., "A New Force Field for Molecular Mechanical Simulation of Nucleic Acids and Proteins," <i>J. Am. Chem. Soc.</i> 106(3):765-784 (1984).	
		WENDOLOSKI, et al., "Biophysical Tools for Structure-Based Drug Design" <i>Pharmacol. Ther.</i> 60(2):169-183 (1993).	
M		WIEDMER, et al. "Complement Proteins C5b-9 Stimulate Procoagulant Activity through Platelet Prothrombinase" <i>Blood</i> 68(4): 875-880 (1986).	
Examiner's Signature	PHILLIP GANON 6/7/99		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96 +
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/020,393
				Filing Date	February 9, 1998
				First Named Inventor	Dr. Peter J. Sims
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	13	of	14	Attorney Docket Number	OMRF 170


OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
M		WIEDMER, et al., "Complement C5b-9-stimulated Platelet Secretion Is Associated with a Ca ²⁺ -initiated Activation of Cellular Protein Kinases," <i>J. Biol. Chem.</i> 262(28):13674-13681 (1987).	
		WIEDMER, et al., "On the Mechanism by Which Complement Proteins C5b-9 Increase Platelet Prothrombinase Activity," <i>J. Biol. Chem.</i> 261(31):14587-14592 (1986).	
		WIEDMER, et al. "Participation of Protein Kinases in Complement C5b-9- Induced Shedding of Platelet Plasma Membrane Vesicles" <i>Blood</i> 78(11):1-7 (1991).	
		WIEDMER, et al. "Role of Calcium and Calpain in Complement-Induced Vesiculation of the Platelet Plasma Membrane and in the Exposure of the Platelet Factor VA Receptor," <i>Biochemistry</i> 29:623-632 (1990).	
		WIEDMER, et al., "Effect of Complement Proteins C5b-9 on Blood Platelets," <i>J. Biol. Chem.</i> 260(13):8014-8019 (1984).	
		WIEDMER, et al., "Cyanine Dye Fluorescence Used to Measure Membrane Potential Changes due to the Assembly of Complement Proteins C5b-9," <i>J. Membr. Biol.</i> 84:249-258 (1985).	
		WURZNER, et al. "Inhibition of Terminal Complement Complex Formation and Cell Lysis by Monoclonal Antibodies" <i>Complement Inflamm.</i> 8: 328-340 (1991).	
		YAMASHINA, et al. "Inherited Complete Deficiency of 20-Kilodalton Homologous Restriction Factor (CD59) as a Cause of Paroxysmal Nocturnal Hemoglobinuria" <i>The New England Journal of Medicine</i> 323(17):1184-1189 (1990).	
		YU, et al., "Mapping the Regions of the Complement Inhibitor CD59 Responsible for Its Species Selective Activity," <i>Biochemistry</i> 36:9423-9428 (1997).	
		YU, et al., "Mapping the Active Site of CD59," <i>J. Exp. Med.</i> 185(4):745-753 (1997).	
M		ZALMAN, et al., "Deficiency of the Homologous Restriction Factor in Paroxysmal Nocturnal Hemoglobinuria," <i>J. Exp. Med.</i> 165:572-577 (1987).	
Examiner's Signature	PHILLIP GIMBER 6/7/98		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


X +	
-----	--



Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

Substitute for form 1449A/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/020,393
				Filing Date	February 9, 1998
				First Named Inventor	Dr. Peter J. Sims
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned <i>1644</i>
Sheet	14	of	14	Attorney Docket Number	OMRF 170

OTHER ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner's Initials*	Cite No. [†]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²		
<i>M</i>		ZALMAN, et al. "Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels," <i>Proc. Natl. Acad. Sci. USA</i> 83: 6975-6979 (1986).			
<i>H</i>		ZHAO, et al., "Identity of the Residues Responsible for the Species-restricted Complement Inhibitory Function of Human CD59," <i>J. Biol. Chemistry</i> 273(17):10665-10671 (1998).			
Examiner's Signature	<i>Daniel P. Fanger 6/8/99</i>		Date Considered		

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.